Drug intelligence / Profile preview

PRGN-3005

Development stage: Phase 1
Lead developer: Precigen
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intraperitoneal

Overview

PRGN-3005 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Precigen Inc. It targets the unshed portion of Mucin 16 (MUC16) and expresses membrane-bound IL-15 (mbIL15) to enhance persistence and a kill switch for safety. It is primarily indicated for the treatment of advanced, recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Brand names: UltraCAR-T
Other names: PRGN-3005 UltraCAR-T cellsPRGN3005 UltraCAR-T cellsPRGN 3005 UltraCAR-T cellsMUC16-targeted CAR-T cellsMUC-16-targeted CAR-T cellsMUC 16-targeted CAR-T cells

Targets

MUC16 (Mucin-16)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on PRGN-3005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRGN-3005.

Explore the full profile